Cytochrome P450c17α (CYP17) gene polymorphism is not associated with leiomyoma susceptibility

Genetics and Molecular Biology

Volumn 25, Issue 4, 2002, Pages 361-364

  Hsieh, Yao Yuan ^a   Tsai, Fuu Jen ^a   Chang, Chi Chen ^a   Tsai, Chang Hai ^a   Lin, Cheng Chieh ^a   Yeh, Lian Shun ^a  

^a CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

CYP17; Cytochrome P450c17; Leiomyoma; Single nucleotide polymorphism

Indexed keywords

CYTOCHROME P450C17; ESTROGEN; RESTRICTION ENDONUCLEASE;

AGAR GEL ELECTROPHORESIS; ALLELE; BASE PAIRING; CONTROLLED STUDY; ESTROGEN SYNTHESIS; FEMALE; GENE AMPLIFICATION; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC CODE; GENETIC MARKER; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; LEIOMYOMA; MAJOR CLINICAL STUDY; PATHOGENESIS; POLYMERASE CHAIN REACTION; RESTRICTION MAPPING; REVIEW; STATISTICAL SIGNIFICANCE;

EID: 0036924044     PISSN: 14154757     EISSN: None     Source Type: Journal    
DOI: 10.1590/s1415-47572002000400002     Document Type: Review

References (23)

1. Bergman-Jungestrom M, Gentile M, Lundin AC and Wingren S (1999) Association between CYP17 gene polymorphism and risk of breast cancer in young women. Int J Cancer 84:350-353.
2. Carey AH, Waterworth D, Patel K, White D, Little J, Novelli P, Franks S and Williamson R (1994) Polycystic ovaries and premature male pattern baldness are associated with one allele of the steroid metabolism gene CYP17. Hum Mol Genet 3:1873-1876.
3. Cohen SR, Thompson JW and Sherman NJ (1988) Congenital stenosis of the lower esophagus associated with leiomyoma and leiomyosarcoma of the gastrointestinal tract. Ann Otol Rhinol Laryngol 97:454-459.
4. Cramer DW (1992) Epidemiology of myomas. Semin Reprod Endocrinol 10:320-324.
5. Diamanti-Kandarakis E, Bartzis MI, Zapanti ED, Spina GG, Filandra FA, Tsianateli TC, Bergiele AT and Kouli CR (1999) Polymorphism T - C (-34 bp) of gene CYP17 promoter in Greek patients with polycystic ovary syndrome. Fertil Steril 71:431-435.
6. Dunning AM, Healey CS, Pharoah PD, Foster NA, Lipscombe JM, Redman KL, Easton DF, Day NE and Ponder BA (1998) No association between a polymorphism in the steroid metabolism gene CYP17 and risk of breast cancer. Br J Cancer 77:2045-2047.
7. Dunning AM, Healey CS, Pharoah PD, Teare MD, Ponder BA and Easton DF (1999) A systematic review of genetic polymorphisms and breast cancer risk. Cancer Epidemiol Biomarkers Prev 8:843-854.
8. Feigelson HS, Coetzee GA, Kolonel LN, Ross RK and Henderson BE (1997) A polymorphism in the CYP17 gene increases the risk of breast cancer. Cancer Res 57:1063-1065.
9. Feigelson HS, Shames LS, Pike MC, Coetzee GA, Stanczyk FZ and Henderson BE (1998) Cytochrome P450c17alpha gene (CYP17) polymorphism is associated with serum estrogen and progesterone concentrations. Cancer Res 58:585-587.
10. Friedman AJ, Rein MS, Pandian MR and Barbieri RL (1990) Fasting serum growth hormone and insulin-like growth factor-I and -II concentrations in women with leiomyomata uteri treated with leuprolide acetate or placebo. Fertil Steril 53:250-253.
11. Habuchi T, Liqing Z, Suzuki T, Sasaki R, Tsuchiya N, Tachiki H, Shimoda N, Satoh S, Sato K, Kakehi Y, Kamoto T, Ogawa O and Kato T (2000) Increased risk of prostate cancer and benign prostatic hyperplasia associated with a CYP17 gene polymorphism with a gene dosage effect. Cancer Res 60:5710-5713.
12. Haiman CA, Hankinson SE, Spiegelman D, Colditz GA, Willett WC, Speizer FE, Kelsey KT and Hunter DJ (1999) The relationship between a polymorphism in CYP17 with plasma hormone levels and breast cancer. Cancer Res 59:1015-1020.
13. Haiman CA, Hankinson SE, Colditz GA, Hunter DJ and De Vivo I (2001) A polymorphism in CYP17 and endometrial cancer risk. Cancer Res 61:3955-3960.
14. Helzlsouer KJ, Huang HY, Strickland PT, Hoffman S, Alberg AJ, Comstock GW and Bell DA (1998) Association between CYP17 polymorphisms and the development of breast cancer. Cancer Epidemiol Biomarkers Prev 7:945-949.
15. Martucci CP and Fishman J (1993) P450 enzymes of estrogen metabolism. Pharmacol Ther 57:237-257.
16. Nedelcheva Kristensen V, Haraldsen EK, Anderson KB, Lonning PE, Erikstein B, Karesen R, Gabrielsen OS and Borresen-Dale AL (1999) CYP17 and breast cancer risk: the polymorphism in the 5′ flanking area of the gene does not influence binding to Sp-1. Cancer Res 59:2825-2828.
17. Picado-Leonard J and Miller WL (1987) Cloning and sequence of the human gene for P450c17 (steroid 17 alpha-hydroxylase/17,20 lyase): similarity with the gene for P450c21. DNA 6:439-448.
18. Rein MS (2000) Advances in uterine leiomyoma research: the progesterone hypothesis. Environ Health Perspect 108:791-793.
19. Spurdle AB, Chen X, Abbazadegan M, Martin N, Khoo SK, Hurst T, Ward B, Webb PM and Chenevix-Trench G (2000) CYP17 promotor polymorphism and ovarian cancer risk. Int J Cancer 86:436-439.
20. Techatraisak K, Conway GS and Rumsby G (1997) Frequency of a polymorphism in the regulatory region of the 17 alpha-hydroxylase-17,20-lyase (CYP17) gene in hyperandrogenic states. Clin Endocrinol (Oxf) 46:131-134.
21. Townsend DE, Sparkes RS, Baluda MC and McClelland G (1970) Unicellular histogenesis of uterine leiomyomas as determined by electrophoresis by glucose-6-phosphate dehydrogenase. Am J Obstet Gynecol 107:1168-1173.
22. Weston A, Pan CF, Bleiweiss IJ, Ksieski HB, Roy N, Maloney N and Wolff MS (1998) CYP17 genotype and breast cancer risk. Cancer Epidemiol Biomarkers Prev 7:941-944.
23. Young IE, Kurian KM, Annink C, Kunkler IH, Anderson VA, Cohen BB, Hooper ML, Wyllie AH and Steel CM (1999) A polymorphism in the CYP17 gene is associated with male breast cancer. Br J Cancer 81:141-143.